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We compared the fever-reducing efficacy of acetaminophen (AA), ibuprofen (IBU), and dexibuprofen 
(DEX) using data collected from the mobile healthcare application FeverCoach, which provides parents 
with guidelines for determining their child’s health condition, according to body temperature. Its 
dataset includes 4.4 million body temperature measurement records and 1.6 million antipyretics 
treatment records. Changes in body temperature over time were compared after taking one of three 
different antipyretics (AA, IBU, and DEX), using a one-way ANOVA followed by a post-hoc analysis. 
A multivariate linear model was used to further analyze the average body temperature differences, 
calibrating for the influences of age, weight, and sex. Children administered IBU had average body 
temperatures that were 0.18 °C (0.17–0.19 °C), 0.25 °C (0.24–0.26 °C), and 0.18 °C (0.17–0.20 °C) lower 
than those of children administered AA, at time intervals of 1–2 hours, 2–3 hours, and 3–4 hours, 
respectively. Similarly, children administered DEX had average body temperatures that were 
0.24 °C (0.24–0.25 °C), 0.28 °C (0.27–0.29 °C), and 0.12 °C (0.10–0.13 °C) lower than those of children 
administered AA, at time intervals of 1–2, 2–3, and 3–4 hours, respectively. Although the data were 
collected from the application by non-professional parents, the analysis showed that IBU and DEX were 
more effective in reducing body temperature than AA was.
Fever is an abnormal increase in body temperature caused by elevation of the hypothalamic set-point1. Infectious 
agents, microbial products, or both as well as cytokines and other inflammatory processes induce macrophages, 
endothelial cells, and the reticuloendothelial system to synthesize and release pyrogenic cytokines such as inter-
leukin (IL)-1 and IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-β and IFN-γ2. These cytokines cause 
the synthesis of prostaglandin E2 (PGE2), which binds to prostaglandin receptors in the hypothalamus to raise 
the thermostatic set point to febrile levels.
Whether fever is beneficial or harmful is controversial. Potential benefits of fever include inhibition of growth 
and reproduction of some bacteria and viruses and improvement of immune function at moderately elevated 
temperatures3,4. In older individuals with community-acquired pneumonia, the mortality rate was significantly 
higher in patients who lacked fever (29%) than in those with fever (4%)5. In a study assessing effects of prophylac-
tic antipyretic use during pediatric vaccination, infants administered paracetamol prophylactically at the start of 
vaccination had lower levels of circulating serotype-specific pneumococcal anticapsular immunoglobulin G for 
five serotypes (3, 4, 5, 6B, and 23 F) than the controls did6.
Although fever plays a role in defending the host from infection, in some situations, it can be more harmful 
than good7,8. Fever increases cardiac output, oxygen consumption, carbon dioxide production, and can exacer-
bate cardiac insufficiency in patients with cardiovascular and pulmonary systems. Therefore, for a child in shock 
or with underlying medical conditions that could be exacerbated by increased metabolic demand, fluid, or elec-
trolyte imbalance, appropriate control of the body temperature is essential.
Antipyretics are commonly used to control body temperature. Acetaminophen (AA), the first antipyretic used 
in modern medicine, and ibuprofen have been the most widely used antipyretics, However the more recently 
developed dexibuprofen (DEX) series has become common in recent years. AA is recommended at doses of 
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10–15 mg/kg and should be administered orally once every 4 hours. The antipyretic effects of AA has an onset of 
between 30 and 60 minutes after administration and normally last for 4 hours9. Side effects of AA include liver 
damage, dizziness, loss of appetite, and skin rash10.
IBU, discovered in the 1960s, is a propionic acid derivative and a member of the antipyretic class of nonsteroi-
dal anti-inflammatory drugs (NSAID)11. IBU is also effective for pain relief and is often used when pain accom-
panies inflammation12. The optimal dose of IBU is 8–10 mg/kg, which should be administered every 6 hours. 
The antipyretic effect of IBU commences between 30 minutes and 60 minutes after administration and its main 
adverse effects are gastrointestinal disorders; allergic reactions affecting the face, tongue, neck, and lips; dyspnea; 
and urticaria13.
The recently developed DEX is a formulation of only the S (+) isomer of IBU. The R (−) IBU has no reducing 
effects, and while R (−) IBU converts to S(+) IBU, the conversion of R (−) ibuprofen is not immediate14. The 
suggested mode of administration of DEX is not very different from that of IBU, except that the optimal DEX 
dose is 5–7 mg/kg.
Many studies have investigated the efficacy of various antipyretics12,14–21. Although fever and pain are both 
nonspecific symptoms, pain usually has a direct effect on a patient’s discomfort. Since antipyretics are also used as 
analgesics, studies of the efficacy of antipyretic drugs have mainly compared their analgesic effects, and relatively 
few have compare their antipyretic effects.
Several clinical studies have compared antipyretic effects according to drug type15–17,19–22. These studies usually 
used a similar research design with experimental groups divided into several categories and a single drug admin-
istration method for every group15,19–22. After a specific treatment period, the difference in body temperature 
reduction was then compared among groups. Usually, the primary endpoint was associated with patient discom-
fort. Randomized control trials (RCTs) and double-blind experiments have typically been performed, but these 
previous studies were limited by including only a small number of study subjects. The number of subjects ranged 
from 3715 to 32620, which may not be enough to explain the difference in efficacy of antipyretics. The studies also 
only compared antipyretic effects after a set time interval, which varied from 30 minutes to 8 hours. In addition, 
these studies were conducted in hospital settings, although antipyretics are not only administered in hospitals.
The shortcomings of these previous studies make them lack the power to effectively explain differences in 
antipyretic effects. Therefore, we decided to investigate the differences in temperature-reducing effects of anti-
pyretics according to type based on real-world data of a large huge number of subjects. We used >4 million and 
>1.6 million user-reported body temperature and antipyretic treatment records, respectively. The large number 
of records is enough to explain the differential efficacy of antipyretics. In addition, we studied the different trends 
of the efficacy of antipyretics at various time intervals. Our hypothesis was that different antipyretics (AA, IBU, 
and DEX) have different temperature-reducing effects.
Results
Table 1 shows the descriptive statistics for the weight, antipyretic dose, sex, and age of children with a record of 
antipyretic treatment. The mean weight and age of the children were significantly different among the antipyretic 
drug types. This expectedly reflected the relative abundance of IBU and DEX prescriptions in older children and 
that of acetaminophen in younger children.
We conducted a one-way analysis of variance (ANOVA) to determine whether there were differences in body 
temperature between the groups administered AA, IBU, and DEX at each time interval. The ANOVA showed that 
the difference between the 0–1 hour and 5–6 hour intervals were statistically significant, and we further analyzed 
the difference between groups using the Games-Howell test. The results are provided in supplemental Tables 1 
and 2. Except for the results of the 0–1-hour time interval in the AA and IBU group, all differences were statisti-
cally significant (P < 0.001). At the 1–2-, 2–3-, and 3–4-hour time intervals, the average body temperatures of the 
IBU and DEX groups differed from that of the AA group by approximately 0.2 °C, while other differences were 
≤0.10 °C.
Table 2 shows the effects of antipyretic type, weight, age, and sex on average body temperature over time 
according to a multivariate linear regression model and the 95% confidence intervals. The IBU group had 
0.18 °C, 0.24 °C, and 0.18 °C (all P < 0.001) lower body temperatures than the AA group did at the 1–2, 2–3, and 
3–4 hour intervals, respectively, controlling for weight, sex, and age. The DEX group had 0.24 °C (P < 0.001), 
0.28 °C (P < 0.001), and 0.12 °C (P < 0.001) lower body temperature than the AA group at the 1–2-, 2–3-, and 
3–4-hour intervals, respectively, controlling weight, sex, and age. The IBU and DEX groups showed lower body 
Variable
Total (n = 217962)
Subgroup by type of antipyretics
AA (n = 82133) IBU (n = 60770) DEX (n = 75059)
Mean
Standard 
deviation Mean
Standard 
deviation Mean
Standard 
deviation Mean
Standard 
deviation P-valuea
Weight (kg) 12.8 3.5 12.5 3.4 13.3 3.8 12.8 3.3 <0.001
Intake (mg/kg) 8.3 3.1 11.9 1.3 7.1 0.9 5.2 0.6 <0.001
Ratio of male sex 0.50 0.50 0.49 0.50 0.24
Age (days) 740.4 501.7 694.6 482.6 782.4 540.4 756.5 485.4 <0.001
Table 1. General characteristics of subjects. aStudent’s t-test used to analyze different distributions of each 
categorical variable by antipyretics group.
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temperatures than the AA group, which was weakened at the 4–5-hour interval and reversed at the 5–6-hour 
interval, as shown in Table 1.
Using the intercept and the coefficients of each antipyretic series from the multivariate linear model, we cal-
culated the average body temperature after excluding the influence of age, sex, and weight (Table 3, Fig. 1). As 
shown in Table 2, IBU and DEX reduced body temperature by >1.0 °C at the 2–3-hour interval compared with 
the average body temperature at the 0–1-hour interval.
To further analyze the varying efficacy of antipyretics in reducing body temperature, subgroup analyses were 
performed. Supplementary Table 3 presents the coefficients of linear regression of IBU and DEX in different age 
subgroups. The 1–5 years old age group showed higher temperature reduction than that of the <1 year old group.
Supplementary Table 4 presents the coefficients of linear regression of IBU and DEX with different initial 
body temperatures. A similar decrease in temperature and recovery trend after antipyretic administration was 
observed in the different subgroups, whereas the body temperatures varied. In particular, in children with body 
temperature ≥40.0 °C, the antipyretics reduced the body temperature by approximately 1.5 °C for AA and 0.2 °C 
more for IBU and DEX.
Variable
Average body temperature at 0–1 hour Average body temperature at 1–2 hour Average body temperature at 2–3 hour
β P 95% CI β P 95% CI β P 95% CI
Intercept
38.76 <0.001 38.75–38.77 38.10 <0.001 38.08–38.11 37.98 <0.001 37.96–38.01
Antipyretics
AA
IBU 0.00 0.132 −0.01–0.00 −0.18 <0.001 −0.19–0.17 −0.25 <0.001 −0.26 to −0.24
DEX 0.02 <0.001 0.01–0.02 −0.24 <0.001 −0.25–0.24 −0.28 <0.001 −0.29 to −0.27
Weight (kg)
0.00 0.906 −0.00–0.00 0.00 <0.001 −0.01 to −0.00 −0.01 <0.001 −0.01 to −0.01
Age (year)
0.00 <0.001 −0.00 to −0.00 0.00 <0.001 0.00–0.00 0.00 <0.001 0.00–0.00
Sex
0.01 <0.001 0.01–0.01 0.02 <0.001 0.02–0.03 0.02 <0.001 0.02–0.03
Variable
Average body temperature at 3–4 hour Average body temperature at 4–5 hour Average body temperature at 5–6 hour
β P-value 95% CI β P-value 95% CI β P-value 95% CI
Intercept
38.12 <0.001 38.09–38.15 38.19 <0.001 38.16–38.23 38.23 <0.001 38.20–38.27
Antipyretics
AA
IBU −0.18 <0.001 −0.20 to −0.17 −0.03 <0.001 −0.04 to −0.02 0.06 <0.001 0.04–0.07
DEX −0.12 <0.001 −0.13 to −0.10 0.07 <0.001 0.06–0.09 0.12 <0.001 0.11–0.13
Weight
−0.01 <0.001 −0.01 to −0.01 −0.01 0.003 −0.01 to −0.00 −0.01 0.001 −0.01 to −0.00
Age
0.00 0.208 −0.00–0.00 0.00 0.021 −0.00 to −0.00 0.00 0.636 −0.00–0.00
Sex
0.00 0.522 −0.01–0.01 −0.01 0.255 −0.02–0.00 0.00 0.924 −0.01–0.01
Table 2. Factors associated with average body temperature at specific time intervals analyzed using multiple 
linear regression. AA: Acetaminophen, IBU: Ibuprofen, DEX: Dexibuprofen, CI: Confidence Interval Unit: °C.
Time interval after 
antipyretic administration 0–1 hour 1–2 hour 2–3 hours 3–4 hour 4–5 hour 5–6 hour
Antipyretics
AA 38.76 38.10 37.98 38.12 38.19 38.23
IBU 38.76 37.92 37.73 37.94 38.16 38.29
DEX 38.78 37.86 37.70 38.00 38.26 38.35
Table 3. Calculated average body temperatures after excluding effects of age, sex, and weight. AA: 
Acetaminophen, IBU: Ibuprofen, DEX: Dexibuprofen, Unit: °C.
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Discussion
This study compares the effectiveness of antipyretics in reducing the body temperature of children based on 
the data collected using a mobile healthcare application, FeverCoach. The data were filtered and categorized 
into three treatment groups: AA, IBU, and DEX. Body temperature records were grouped according to the time 
after administration of the antipyretics. Mean body temperatures were calculated to examine general trends 
in the temperature-reducing effects. A one-way ANOVA and post-hoc analysis were used to calculate differ-
ences in body temperatures among the groups and Multivariate linear regression was used to compare the 
temperature-reducing effect of IBU and DEX treatment with that of AA, controlling for sex, age, and weight. Our 
analysis showed that IBU and DEX exhibited better antipyretic effects than AA did, at time intervals of 1–4 hours.
Figure 1 shows that the antipyretics clearly reduced body temperature, which was maximal at the 2–3-hour 
interval. Additionally, the average body temperature started to rise above 38.0 °C at the 4–5-hour interval. These 
results are consistent with those other studies of the effective duration of antipyretic action9, corroborating the 
validity of the FeverCoach database. Based on our analysis, we suggest a guideline to recommend alternating anti-
pyretics and encouraging parents to observe and measure the body temperature of children for at least approxi-
mately 2 hours. This is because some parents are often anxious when their child has a fever, leading to excessive 
administration of antipyretics.
The results of the comparison between AA and IBU demonstrated that from the 1–2-hour interval to the 
3–4-hour interval, IBU treatment reduced body temperature by approximately 0.2 °C more than AA treatment 
did, controlling for the influence of weight, age, and sex. Previous studies also compared the antipyretic efficacy 
of AA and IBU, but the results are not in consensus15,16,20–22. While one study found no significant differences 
between the effects of AA and IBU21, a few other studies suggested that IBU offers better antipyretic effects than 
those of AA16,20,22. A meta-analysis reported that IBU may have better antipyretic effects than AA16. Our results 
support previous findings that IBU administered at the proper dose was more effective at reducing body temper-
ature than AA was16,20,22.
The results of the comparison between AA and DEX were similar to those of the comparison between AA 
and IBU. The DEX group had an approximately 0.2 °C lower average body temperature than the AA group did 
in the 1–4-hour interval. These results show that DEX reduced body temperature better than AA did, when 
properly prescribed. The antipyretic effect of DEX has been previously verified19, but no studies have compared 
it with those of AA. To the best of our knowledge, this is the first work to compare the temperature-reducing 
effects of AA and DEX. We suggest that since DEX and IBU have nearly the same reaction pathway, their 
temperature-reducing effects area also similar.
The superior antipyretic efficacy of IBU and DEX over AA reversed from the 4–5-hour time interval to the 
5–6-hour time interval. The average body temperatures of the IBU and DEX groups were 0.06 °C and 0.12 °C 
higher, respectively than that of the AA group was at the 5–6-hour time interval, which is considerable. This may 
suggest that the onset of the temperature-reducing effect of IBU and DEX is shorter than that of AA. Further stud-
ies should be conducted to compare the onset time of the temperature-reducing effects of different antipyretics.
The comparison between IBU and DEX showed they exhibited similar effects on reducing body temperature. 
The body temperature difference at each time interval between IBU and DEX did not exceed 0.1 °C. Therefore, 
we concluded that IBU and DEX are not very different in terms of antipyretic effect. This result is also consistent 
with that of a previous study, which found that DEX had a similar temperature-reducing effect to that of IBU19.
The overall comparison shows the similar antipyretic effect of IBU and DEX, which is better than that of AA 
in 1–4-hour time interval. This analysis may provide evidence to support the clinical use of IBU and DEX rather 
than AA in diseases where body temperature management is important such as febrile convulsion and neurologic 
diseases including Moyamoya disease. The exception would be where there is a specific contraindication for 
administering IBU and DEX.
Subgroup analysis showed that for children aged 1 to 5, the observed decreases in body temperature after 
antipyretic administration were greater, and the difference between AA and IBU or DEX were also larger at time 
intervals of 1–4 hours than at other intervals. However, since the initial body temperature, which influences the 
quantitative reduction was high, further analysis should be conducted to determine why initial body tempera-
tures of the 1 to 5 years old subgroup were higher.
Figure 1. Change in average body temperatures over time, according to antipyretic type.
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Subgroup analysis also showed that children with high fever (≥40 °C) exhibited a dramatic reduction in body 
temperature. However, the reduction may not be solely due to drug efficacy because a variety of cooling methods 
could have been used by parents according to the app’s guide. However, the efficacy difference observed between 
AA and IBU or DEX was consistent in this subgroup, which is noteworthy.
This study has some limitations associated with the nature of the data used. First, the data were recorded 
by parents who are usually not professional health care providers. Therefore, the method and position used for 
temperature measurement and thermometer type may have differed among patients. Furthermore, parents may 
have made other efforts to decrease the children’s body temperature, especially because the application provides 
a detailed guide for this. In addition, in some cases, the accurate body temperature may not have been recorded. 
Another weakness is that while we did not exclude the records of children taking antibiotics because the data were 
unavailable, antibiotics could also affect children’s fever. We did not include neonates and children <6 months 
old or those who alternated antipyretics, so further study would be needed to analyze the efficacy of alternating 
antipyretics.
Despite these limitations, this study also has several strengths compared with previous studies. For instance, 
our results are based on an incomparably larger self-reported dataset than those used in previous studies. The 
small sample sizes of previous studies may have decreased their explanatory power. A large self-reported dataset 
not only has excellent explanatory power when properly filtered, but also better mimics a real-world setting. 
Furthermore, to the best of our knowledge, this study is the first to compare AA, IBU, and DEX. Although previ-
ous studies have compared the temperature-reducing efficacy of two types of antipyretics, most focused on com-
paring AA and IBU. To the best of our knowledge, this is the first study to compare the antipyretic effect between 
an AA-treated and DEX-treated group.
In conclusion, IBU and DEX were more effective in reducing body temperature than AA was and they showed 
no apparent differences in clinical efficacy of their antipyretic effects, which suggests they likely have similar 
mechanisms of body temperature reduction. The average cost (US dollar/kg) of DEX is 3.7 times more than 
that of IBU23,24. The choice of antipyretics for children may be influenced by the underlying medical condition, 
chronic medications, adverse effects, and cost-benefit ratio. Consequently, the decision on the type of antipyretic 
to use in children should be made on a case-by-case basis.
Methods
Mobile healthcare application, fevercoach. FeverCoach is a mobile healthcare application targeted 
at parents with children exhibiting various symptoms, including fever. The application provides parents with 
guidelines to assess a child’s condition and is especially useful for parents who cannot go to the hospital. This 
application allows parents to effectively and accurately control fever symptoms. The application mainly offers the 
following functions: data storage for each child’s body temperature, guidance on antipyretic drug administration, 
and general pediatric health information. Detailed explanations of the application and its data storage method 
and screenshots of the application are provided in Appendix 1.
The application was released more than 2 years ago, and it has continued to accumulate data. From July 2015 
to June 2017, approximately 4.4 million body temperature and approximately 1.6 million antipyretic treatment 
records were accumulated. We believe that this dataset could be very valuable for use in a variety of services or 
studies.
Data and study population. For this study, we mainly extracted two types of data from the FeverCoach 
database: body temperature measurement and antipyretic treatment records. To guarantee the validity of the 
analysis, we filtered records by various conditions.
Body temperature measurement records. Parents input three values (body temperature, time of body 
temperature measurement in minutes, and vaccination information) after measuring their child’s body tempera-
ture, which was recorded to the first decimal place. Whether the child had a vaccination within the last 48 hours 
is also input because vaccinations can significantly affect body temperature. Every measurement is stored in the 
FeverCoach database with time-stamped identifier variables that distinguish each child. There were 4,424,820 
body temperature measurements recorded in the dataset.
Antipyretic treatment records. Parents input five values (administration method, antipyretic type, prod-
uct name, dosage, and treatment time) after antipyretic administration to their child. Parents had four admin-
istration methods to choose from (potions, powder, pills, and suppositories) and three antipyretic types (AA, 
IBU, and DEX). Parents also had the option to input the drug’s product name. Treatment doses were entered in 
milliliters or milligrams, and treatment time was entered in minutes. Similarly, every treatment record was stored 
with identifier variables that distinguish each child and a timestamp. There were 1,630,707 antipyretics treatment 
records in the dataset.
Study population. Because our results were derived from self-reported data, it was especially crucial to filter 
out inadequate records in the database. Our inclusion and exclusion flowchart is provided in Fig. 2. We excluded 
records incomplete age or weight data. Children >12 years old or <6 months and those weighing >40 kg or <5 kg 
were considered to potentially undermine the validity of our analyses and were excluded. Six months was chosen 
as the lower age cutoff because children younger than 6 months are prohibited from being prescribed IBU and 
DEX. The upper age cutoff of 12 years old was chosen because children >12 years old are administered the adult 
dose. At least 99% of the 6-month-old children weighed at least 5 kg, and the top 50% of 12-year-old children 
weighed at least 40 kg.
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Furthermore, invalid antipyretic administration was excluded from our analysis. All body temperature meas-
urements not recorded within 6 hours after antipyretic treatment were considered inadequate and, therefore, 
were excluded. Additionally, we excluded any records of antipyretics not administered orally and those where 
patients received additional treatment within 6 hours. We focused on orally administered drugs because children 
rarely take IBU and DEX via other routes. Records with more than one antipyretic treatment in 6 hours (alternat-
ing antipyretic intakes or records of same drug administration) were also excluded. Specifically, among 97,269 
records excluded because of more than one administration of antipyretics in 6 hours, 35,926 were administered 
AA twice, 23,128 IBU twice, 29,047 DEX twice, 3,468 AA and IBU, 3,007 IBU and DEX, 2,590 DEX and AA, and 
103 were administered all three agents (AA, IBU and DEX). Finally, we also excluded data of body temperatures 
taken within 5 minutes of administering antipyretic treatment and those that were lower than 38.0 °C, because 
antipyretics are only supposed to be administered when the patient is feverish.
After our exclusions, 217,962 of the 1,630,707 antipyretic treatment records were analyzed, consisting of 
82,133, 60,770, and 75,059 AA, IBU, and DEX treatment records, respectively.
Ethical considerations. All data were anonymized at the time of storage. In addition, the Yonsei University 
Health System Institutional Review Board (IRB), Seoul, Korea provided formal ethics approval of this study 
(IRB approval number 4-2017-1074) that waived the need for informed consent as part of the study approval. 
Consequently, the data analysis was performed without requiring consent from the participants.
Variables. The main independent variable for our analysis was antipyretic type, which was catego-
rized into three groups: AA, IBU, and DEX. The age, weight, and sex of a child are well known to influence 
temperature-reducing effects and, therefore were also included in the analysis.
We included body temperature as a dependent variable with six time intervals: 0–1, 1–2, 2–3, 3–4, 4–5, and 
5–6 hours. Previous studies fixed the time interval between antipyretic treatment and body temperature meas-
urements. However, as our data was user-recorded, the time intervals between antipyretic treatment and body 
temperature measurements were random. Therefore, we divided the body temperature measurements after anti-
pyretic treatment by 1-hour intervals. For a single antipyretic treatment record, if multiple body temperature 
measurements were recorded in the same 1-hour interval, the average of those records was calculated for that 
Figure 2. Inclusion and Exclusion flow chart.
7Scientific RepoRtS |         (2020) 10:3879  | https://doi.org/10.1038/s41598-020-60193-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
time interval. For a single antipyretic treatment record, if no records existed in a single time interval, the data 
field for that time interval was left empty. Therefore, only records with at least one observation in a 1-hour time 
interval were included in the analysis of that time interval.
Statistical analysis. We first examined the general characteristics of antipyretic records. The Student t-test 
was performed to analyze differences in populations between antipyretic drug groups. Averages and standard 
deviations of body temperatures by time interval were calculated for the data on the three groups of antipyretics 
(AA, IBU, DEX). A one-way ANOVA and post-hoc test were performed to compare average body temperatures 
of the three antipyretic groups. Because the data size was large enough, we choose ANOVA for the analysis, which 
also enabled the calculation of the effect size in degrees Celsius, which is easy to interpret for both researchers 
and clinicians. Temperature changes over time were analyzed as categorical variables. Next, we performed multi-
variate linear regression analysis to investigate the relationships between antipyretic type and other independent 
variables, after stratifying body temperature by time interval. Dose was not included in the model since the opti-
mal dose differed by antipyretic type, making a pair-wise comparison between two drugs difficult. Instead, only 
records that adhered to the optimal dose were included in the analysis. Finally, data were subgrouped by age and 
initial body temperature. Effect sizes for variables were also calculated using the coefficients of linear regression. 
The AA group was used as the reference in our models. We determined that P-values <0.05 indicated statisti-
cal significance. All statistical analyses were performed using R statistical software (Foundation for Statistical 
Computing, Vienna, Austria), a free software program for statistical computation and graphical presentation.
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